Fresh off the heels of mega fi­nanc­ing round, Ger­many's BioN­Tech makes $100M US IPO play

Two months af­ter one of the largest sin­gle pri­vate fund­ing rounds for a biotech com­pa­ny in Eu­ro­pean his­to­ry, Ger­man can­cer drug de­vel­op­er BioN­Tech is gun­ning for a $100 mil­lion US IPO.

Hel­mut Jeg­gle

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER